Driving small molecule antiviral development for Respiratory Syncytial Virus infection

RSV: Serious Unmet Medical Need
  • RSV is a common and serious cause of respiratory infection in children, the immune-compromised and the elderly
  • The World Health Organization (WHO) estimates that RSV causes 64 million infections and 160,000 infant deaths each year
  • It is the most important respiratory virus, responsible for one-fifth of all lower respiratory tract infections worldwide
  • There are no effective treatments or vaccines available against RSV

Leading the Way: RV521

  • An RSV fusion (F) protein inhibitor
  • Best-in-class drug to treat RSV infections
  • Completed Phase 1 studies with antiviral exposures achieved
  • Completed RSV challenge model with high potency against both viral load and symptoms
  • Excellent safety profile
  • Entering an international multicentre Phase 2 paediatric trial

Meet the Team...
Latest News
ReViral Announces Grant of Key US Composition of Matter Patent For Their Respiratory Syncytial Virus inhibitor programme

• Patent claims RSV fusion protein inhibitors as medicines including lead pipeline candidate, RV521; patent nominally expires in 2035 (unextended)
• The...

ReViral to present at Microbiology Society Annual Conference 2019

ReViral's Chief Scientific Officer, Stuart Cockerill, will be giving an oral presentation at the Microbiology Society Annual Conference 2019 (8th-11th April) in Belfast. The...

Virologist Position (Durham Area)

ReViral are currently recruiting a Virologist to join our laboratory team based in the Durham area, UK, to support the company's antiviral drug discovery and development...

Contact us...
Privacy Policy